The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels  by Chang, Chang-Chi et al.
ORIGINAL ARTICLE
Urol Sci 2010;21(2):88−92
88 ©2010 Taiwan Urological Association. Published by Elsevier Taiwan LLC.
The Significance of Plasma C-reactive Protein in Patients 
With Elevated Serum Prostate-specific Antigen Levels
Chang-Chi Chang1,2,3, Alex T.L. Lin2,3*, Kuang-Kuo Chen2,3, Hsiao-Jen Chung2,3, 
Shyh-Chyi Chang2,3,4
1Division of Urology, Department of Surgery, Taipei City Hospital, Taipei, Taiwan
2Division of Urology, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
3Department of Urology, National Yang-Ming University, School of Medicine, Taipei, Taiwan
4Division of Urology, Department of Surgery, Lo-Tung Pohai Hospital, Lo-Tung, Taiwan
Objective: Prostatic infection/inflammation may increase serum prostate-specific 
antigen (PSA) levels. We hypothesized that prostatic infection/inflammation can be 
identified by elevated plasma C-reactive protein (CRP) levels. Measuring plasma 
CRP levels may help to differentiate benign conditions from prostate cancer in pa-
tients with elevated serum PSA levels.
Materials and Methods: A total of 139 patients with serum PSA levels greater than 
4.0 ng/mL received transrectal ultrasound guided biopsy. All of the patients had 
plasma high-sensitivity CRP levels measured. CRP levels higher than 0.5 mg/dL were 
considered abnormal. CRP and PSA levels, and prostate size were compared be-
tween benign and malignant groups. The association of CRP levels with cancer stages 
was also analyzed.
Results: Thirty-four out of 139 (24.5%) patients were found to have prostate cancer. 
There was no significant difference in CRP levels between the malignant and benign 
groups. Five out of 34 (14.7%) patients with prostate cancer and 13 of 105 (12.4%) 
patients with benign lesions had elevated CRP levels. The incidence of abnormal 
CRP levels was not significantly different between the groups (p = 0.77). Patients 
with high PSA and CRP levels did not have a higher probability of a benign condition. 
It is interesting to note that in the malignant group, there was a significant positive 
correlation between CRP and PSA levels (r = 0.44, p = 0.01). No significant correlation 
between CRP levels and cancer stages was noted.
Conclusion: Measuring plasma CRP levels does not assist in the identification of be-
nign conditions in patients with elevated PSA levels. However, plasma CRP levels are 
well-correlated with serum PSA levels in prostate cancer patients, suggesting a po-
tential correlation between prostate inflammation and prostate cancer.
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1.  Introduction
Prostate-specific antigen (PSA) is produced exclusively by 
epithelial cells of the prostate gland. Disruption of the 
cell-to-cell architecture of prostate epithelium results in 
increased serum PSA levels.1 Apart from prostate cancer, 
nonmalignant conditions and prostate manipulation such 
as benign prostatic hyperplasia (BPH), acute/chronic pros-
tatitis, prostate infarction, cystoscopy, biopsy of the pros-
tate gland, prostate massage, and urinary catheterization 
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elevate serum PSA levels.2,3 PSA levels alone are not a re-
liable discriminator between prostate cancer and benign 
conditions of the prostate.
Subclinical prostate inflammation is one of the most 
important factors contributing to elevation of serum 
PSA levels.4 Currently, other than prostate biopsy, there 
is no other reliable method to detect prostate inflam-
mation. We speculated that elevated serum C-reactive 
protein (CRP) levels might serve as an indicator for intra-
prostatic inflammation. CRP is a surrogate for interleukin 6 
(IL-6) action.5 IL-6 plays an important role in immune 
and acute-phase inflammatory responses and acts on 
hepatocytes to increase the synthesis of CRP and other 
acute phase reactant proteins (e.g., hepatoglobin and 
fibrinogen).6 CRP is a non-specific but fairly sensitive 
marker of acute-phase inflammation. The common condi-
tions associated with major elevations of CRP levels are 
bacterial infection (e.g., pyelonephritis and endocarditis), 
inflammatory diseases (e.g., rheumatoid arthritis, Crohn 
disease and Reiter disease), cancer, tissue necrosis (myo-
cardial infarction and tumor embolization), and trauma.
We hypothesized that plasma CRP levels, which are a 
sensitive marker for inflammation, may reflect prostatic 
infection/inflammation. The aim of the present study was 
to determine whether plasma CRP levels can differenti-
ate benign conditions from prostate cancer in patients 
with elevated serum PSA levels.
2.  Materials and Methods
The study was granted approval from the Division of 
Urology, Taipei Veterans General Hospital. One hundred 
thirty-nine patients who had serum PSA levels > 4.0 ng/
mL and had received transrectal ultrasound-guided 
six- or eight-core needle biopsy of the prostate were en-
rolled in the current study after getting informed con-
sents. None of the patients had documented acute 
prostatitis or urinary tract infection. For each patient, 
plasma high-sensitivity CRP levels were measured be-
fore transrectal ultrasound guided biopsy. A CRP level 
≥ 0.5 mg/dL was considered abnormal.7
Based on the pathologic results, we divided all pa-
tients into two groups: the malignant group (prostate 
cancer, n = 34) and the benign group (n = 105). Both groups 
were stratified into two subgroups by plasma CRP levels 
as follows: normal CRP (< 0.5 mg/dL) and abnormal CRP 
(≥ 0.5 mg/dL). The following parameters were compared 
between the benign and malignant groups: mean age, 
plasma CRP levels, serum PSA levels, and prostate size 
(volume = prostate length [cm] × width [cm] × depth [cm] × 
0.52) based on a previous report.8 Correlations of plasma 
CRP levels with serum PSA levels and prostate size were 
evaluated. Additionally, in the malignant group, the as-
sociation between plasma CRP levels and cancer stage 
(T1, T2, T3, metastasis) was evaluated. The stage was 
determined based on the TNM staging system (American 
Joint Committee on Cancer, 2002).9 The t test, Fisher exact 
test, Pearson correlation test, and one-way analysis of 
variance were used to determine statistical significance, 
which was set at p < 0.05.
3.  Results
Thirty-four out of 139 patients (24.5%) were found to 
have prostate cancer. The baseline characteristics in both 
groups of patients are shown in Table 1. The mean serum 
PSA level was higher in the malignant group than that 
in the benign group (53.0 ± 101.9 vs. 8.8 ± 5.4 ng/mL; 
p = 0.02). However, prostate size was significantly larger 
in the benign group than that in the malignant group 
(55.5 ± 30.0 cm3 vs. 41.0 ± 21.0 cm3; p = 0.01).
There was no significant difference in CRP levels be-
tween the malignant and benign groups. Five out of 34 
patients with prostate cancer (14.7%) and 13 out of 105 
patients with benign lesions (12.4%) had elevated CRP 
levels. The incidence of abnormal CRP levels was not 
significantly different between the groups (p = 0.77). 
Can cer detection rates did not differ between the ab-
normal CRP and normal CRP subgroups (27.8% [5 of 18] 
vs. 24.0% [29 of 121]; p = 0.77).
Plasma CRP levels were positively correlated with serum 
PSA levels only in those patients with prostate cancer 
(r = 0.44, p = 0.01; Table 2). Although there was no signifi-
cant correlation between CRP levels and cancer stages 
(T1, T2, T3, metastasis) (one-way ANOVA, p = 0.16), CRP 
levels tended to be higher in patients with metastatic pros-
tate cancer than in those with non-metastatic prostate 
cancer.
Table 1   Baseline characteristics of the malignant and benign groups*
Characteristic Malignant group (n = 34) Benign group (n = 105) p†
Age (yr) 73.4 ± 9.1 (45–89) 71.1 ± 9.3 (35–90) 0.21
CRP (mg/dL) 0.3 ± 0.3 (0.02–1.46) 0.4 ± 1.1 (0.02–8.23) 0.47
PSA (ng/mL) 53.0 ± 101.9 (4.05–453) 8.8 ± 5.4 (4.04–34.88) 0.02
Prostate size‡ (cm3) 41.0 ± 21.0 (19.4–124.0) 55.5 ± 30.0 (13.8–205.8) 0.01
*Data presented as mean ± standard deviation, with ranges in parentheses; †t test; ‡volume = length (cm) × width (cm) × depth (cm) × 0.52. 
CRP = C-reactive protein; PSA = prostate-specific antigen.
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We also found that patients who had high serum PSA 
levels combined with elevated CRP levels did not have a 
higher probability of benign conditions (Table 3).
4.  Discussion
Increased serum PSA levels are an important indicator for 
prostate cancer. However, PSA levels are prostate-specific 
but not cancer-specific.10 Adenocarcinoma of the pros-
tate, as well as BPH and prostatic infection/inflammation 
(acute/chronic, symptomatic/asymptomatic), can cause 
elevation of serum PSA levels.1,2,11,12
It is well known that both malignancy and inflamma-
tion of benign prostates can elevate serum PSA levels. 
Pansadoro et al.3 reported that the incidence of in-
creased PSA levels is high in acute bacterial prostatitis. 
Brawer et al.13 observed that elevated PSA levels are 
found in 69% and 4% of patients with acute and chronic 
inflammation in prostatic tissue, respectively. Acute in-
flammation is thought to be the more important contrib-
utor to PSA elevation according to previous reports.13–15 
Conversely, in a study of PSA-based prostate cancer 
screening, many of the prostate biopsy specimens that 
did not show cancer showed inflammation, although 
there were no symptoms to suggest prostatitis.4 A total 
of 98.1% of patients who undergo prostatectomy or 
transurethral resection of the prostate have histologic 
inflammation.16 In the current study, symptoms and signs 
of acute prostatitis were exclusion criteria. Therefore, it 
is doubtful whether subclinical (asymptomatic) prostatic 
inflammation increases serum PSA levels as well. Nickel 
et al.17 demonstrated that histologic (subclinical) pros-
tatitis is an extremely common finding in prostate biop-
sies taken in men without clinical inflammation. Irani 
et al.18 concluded that inflammation seen on prostate 
biopsies is not significantly related to serum PSA levels 
unless associated with glandular epithelial disruption (ag-
gressiveness). Several reports have shown that histologic 
inflammation is significantly correlated with serum PSA 
levels.4,19
Plasma CRP levels have been proposed to reflect in-
flammation in the prostate and might be related to the 
severity of lower urinary tract symptoms (LUTS) in BPH 
patients. Drachenberg et al.20 found higher serum IL-6 
levels in men with BPH, and serum IL-6 levels were often 
associated with prostatic inflammation. Theoretically, 
plasma CRP levels, which are a marker of inflammation, 
might be higher in men with BPH, because production 
of CRP is induced by IL-6. In a series of 2377 men with 
LUTS, there was a non-statistically significant but posi-
tive association between serum CRP levels and LUTS, 
which was suggestive of BPH.21 The investigators sug-
gested that serum CRP levels might be an indicator of 
intraprostatic inflammation in symptomatic BPH.21 Based 
on these reported observations, we speculated that pa-
tients with LUTS and a higher CRP level may have pros-
tatic inflammation and associated abnormal PSA levels. 
In other words, patients with abnormal PSA levels and 
elevated CRP levels might have a higher probability of 
benign lesions than those with abnormal PSA levels and 
normal CRP levels. However, we found that mean plasma 
CRP levels and the incidence of abnormal plasma CRP 
levels were not significantly different between the ma-
lignant and benign groups. Patients with high PSA and 
CRP levels did not have a higher probability of benign 
conditions. It appears that prostate inflammation may not 
universally induce an elevation in CRP levels. It is also 
possible that prostate inflammation is involved both in 
BPH and prostate cancer, indicating that plasma CRP lev-
els are an unreliable marker for differential diagnosis.
Chronic inflammation has been advocated to play a 
role in the pathogenesis of prostate cancer. Inflammatory 
infiltrates are observed in and around foci of proliferative 
inflammatory atrophy, which have a high proliferative in-
dex as well as frequent association with inflammation.22 
Proliferative inflammatory atrophy, which occurs diffusely 
in the anatomic peripheral zone of the prostate where 
prostate cancer predominantly develops, has been sug-
gested to be the precursor of prostate cancer or indicator 
of prostatic environment favorable to carcinogenesis.23 
Studies have revealed that regular use of non-steroidal 
anti-inflammatory drugs may reduce the risk of prostate 
cancer.24 In this study, we observed a significant positive 
correlation between CRP and PSA levels in the malignant 
group, further suggesting a correlation between pros-
tatic inflammation and prostate cancer. Lehrer et al.25 
also found a positive correlation between CRP and PSA 
Table 2   Correlation of C-reactive protein (CRP) with prostate-
specific antigen (PSA) levels and prostate size in 
malignant and benign conditions
 Malignant group Benign group
 (n = 34) (n = 105)
 r p* r p*
CRP–PSA* 0.44 0.01  0.15 0.14
CRP–prostate size* 0.26 0.14 –0.03 0.74
*Pearson correlation test. r = Pearson product-moment correlation 
coefficient.
Table 3   The probability of a benign condition when prostate-
specific antigen (PSA) and C-reactive protein (CRP) 
levels are high
PSA level CRP level Benign condition,
(ng/mL) (mg/dL) n (%)
 > 4 ≥ 0.5  13/18 (72.2)*
 > 4 < 0.5 92/121 (76.0)*
*Fisher exact test; p = 0.77.
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levels in their prostate cancer patients. Furthermore, 
CRP levels in men with metastatic prostate cancer are 
higher than in those with non-metastatic disease.26 In 
the current study, although we failed to demonstrate a 
statistically significant difference in CRP levels between 
patients with metastatic disease and localized prostate 
cancer, CRP levels tended to be higher in patients with 
metastatic prostate cancer. Trautner et al.27 found that 
elevated CRP levels are associated with a higher proba-
bility of tumor recurrence and poor prognosis. Elevated 
CRP levels appear to be an indicator of tumor progres-
sion, recurrence, and less favorable prognosis.
In the present study, a positive correlation between 
plasma CRP levels and serum PSA levels was observed 
only in the malignant group but not in the benign group. 
Possible explanations for this finding may be as follows. 
First, the abnormal plasma CRP values were 0.509, 0.557, 
0.607, 0.685, 0.819, 0.834, 0.91, 1.35, 3.3, 3.5, 4.79, 5.7, 
8.23 mg/dL in the benign group and 0.594, 0.609, 0.873, 
1.14, 1.46 mg/dL in the malignant group. According to 
our abnormal CRP data, five individuals with benign pro-
static diseases had particularly high plasma CRP levels 
(> 3 mg/dL). We speculate that these surprisingly high 
plasma CRP levels in the benign group might have been 
produced by unknown factors other than the prostate 
gland, such as cardiovascular disease, injury or even 
other cancers, thus resulting in no association between 
plasma CRP levels and serum PSA levels in patients with 
benign prostatic diseases. In prostate cancer patients, the 
synthesis of CRP is also stimulated by IL-6, and therefore, 
elevated levels of IL-6 might cause elevated CRP levels.28 
Moreover, Shariat et al.29 showed that direct local pro-
duction of IL-6 by malignant cells significantly contributes 
to increased circulating levels of IL-6 in patients with 
prostate cancer. They also found a correlation between 
circulating IL-6 and PSA levels. These findings are con-
sistent with our finding of a positive correlation between 
plasma CRP levels and serum PSA levels in the malignant 
group.
In summary, our results indicate that plasma CRP lev-
els do not help distinguish between benign and malig-
nant prostatic conditions in men with elevated PSA 
levels. However, plasma CRP levels are well-correlated 
with serum PSA levels in prostate cancer patients, sug-
gesting a potential correlation between prostate inflam-
mation and prostate cancer.
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